MediciNova Inc
MNOV.OQ- Latest Trade
- trading higher2.47USD
- 0
- 0.00%
- As of Jan 27 2023. Values delayed up to 15 minutes
- Day Range
- 2.47 - 2.52
- 52-Week Range
- 1.96 - 3.18
- Previous Close
- 2.47
- Open
- 2.52
- Volume
- 3,429.00
- 3 Month Average Trading Volume
- 1.76
- Shares Out (Mil)
- 49.05
- Market Cap
- 117.22
- Forward P/E
- -8.26
- Dividend Yield
- 0.00
Key Statistics
2 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 0.00
- Price To Book (Quarterly)
- 1.60
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -16.31
- Return On Equity (TTM)
- -15.47
2021 (millions USD)
About MediciNova Inc (MNOV.OQ)
Company Information
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
Address
SUITE 650, 4275 EXECUTIVE SQUARELA JOLLA, CA
92037
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Jeffrey Himawan
- Independent Chairman of the Board
- Yuichi Iwaki
- President, Chief Executive Officer, Director
- Jason J. Kruger
- Chief Financial Officer
- Federico Gaeta
- Chief Scientific Officer
- Geoffrey G. O'brien
- Vice President
- Kazuko Matsuda
- Chief Medical Officer, Director
- David H. Crean
- Chief Business Officer
- Carolyn D. Beaver
- Independent Director
- Hideki Nagao
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,929.10 | -- |
| Copper | 783.30 | 1.20% |
| Brent Crude Oil | 86.33 | 1.30% |
| CBOT Soybeans | 1,512.25 | 0.74% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,070.56 | 0.25% |
| Euro STOXX 50 | 4,178.01 | 0.10% |
| FTSE 100 | 7,765.15 | 0.05% |
| Nikkei 225 | 27,382.56 | 0.07% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes